Roles of toll-like receptors in cancer: A double-edged sword for defense and offense

Archives of Pharmacal Research

Volumn 35, Issue 8, 2012, Pages 1297-1316

  Basith, Shaherin ^a   Manavalan, Balachandran ^b   Yoo, Tae Hyeon ^a   Kim, Sang Geon ^c   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

^b Korea Institute for Advanced Study   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Antitumor; Inflammation; Proinflammatory cytokines; Toll like receptor; Tumor immunotherapy; Tumorigenesis

Indexed keywords

AGATOLIMOD; ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; BROPIRIMINE; CBLB 502; CHAPERONIN 60; CPG 10101; CPG OLIGODEOXYNUCLEOTIDE; EMEPEPIMUT S; ERLOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMO 2055; IPH 3102; ISATORIBINE; ISS 1018; LIPOPEPTIDE; LOXORIBINE; MGN 1703; MGN 1706; OLIGONUCLEOTIDE; OM 174; PHOSPHORYL LIPID A; PICIBANIL; RESIQUIMOD; RITUXIMAB; SMP 105; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VTX 2337; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ASTROCYTOMA; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; EPITHELIUM CELL; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; GLIOBLASTOMA; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; LARYNX CARCINOMA; LUNG CANCER; MACROPHAGE; MONOCYTE; NEOPLASM; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN METASTASIS; SKIN TUMOR; STOMACH CANCER; TISSUE REPAIR; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84868101247     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0802-7     Document Type: Review

References (150)

1. Akira, S., Uematsu, S., and Takeuchi, O., Pathogen recognition and innate immunity. Cell, 124, 783-801 (2006). (Pubitemid 43261452)
2. Balkwill, F. and Coussens, L. M., Cancer: an inflammatory link. Nature, 431, 405-406 (2004). (Pubitemid 39329565)
3. Balkwill, F. and Mantovani, A., Inflammation and cancer: back to Virchow? Lancet, 357, 539-545 (2001). (Pubitemid 32173595)
4. Basith, S., Manavalan, B., Lee, G., Kim, S. G., and Choi, S., Toll-like receptor modulators: a patent review (2006-2010). Expert Opin. Ther. Pat., 21, 927-944 (2011).
5. Bassi, P., BCG (Bacillus of Calmette Guerin) therapy of highrisk superficial bladder cancer. Surg. Oncol., 11, 77-83 (2002). (Pubitemid 34603366)
6. Bauer, A. K., Dixon, D., Degraff, L. M., Cho, H. Y., Walker, C. R., Malkinson, A. M., and Kleeberger, S. R., Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J. Natl. Cancer Inst., 97, 1778-1781 (2005). (Pubitemid 41782287)
7. Beg, A. A., Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol., 23, 509-512 (2002). (Pubitemid 35223541)
8. Berger, R., Fiegl, H., Goebel, G., Obexer, P., Ausserlechner, M., Doppler, W., Hauser-Kronberger, C., Reitsamer, R., Egle, D., Reimer, D., Muller-Holzner, E., Jones, A., and Widschwendter, M., Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci., 101, 1059-1066 (2010).
9. Blander, J. M. and Medzhitov, R., Regulation of phagosome maturation by signals from toll-like receptors. Science, 304, 1014-1018 (2004). (Pubitemid 38638100)
10. Brignole, C., Marimpietri, D., Di Paolo, D., Perri, P., Morandi, F., Pastorino, F., Zorzoli, A., Pagnan, G., Loi, M., Caffa, I., Erminio, G., Haupt, R., Gambini, C., Pistoia, V., and Ponzoni, M., Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res., 70, 9816-9826 (2010).
11. Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., Didonato, J. A., Feinstein, E., and Gudkov, A. V., An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-230 (2008). (Pubitemid 351521417)
12. Butts, C., Maksymiuk, A., Goss, G., Soulieres, D., Marshall, E., Cormier, Y., Ellis, P. M., Price, A., Sawhney, R., Beier, F., Falk, M., and Murray, N., Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol., 137, 1337-1342 (2011).
13. Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulieres, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., Davis, M., Mansi, J., Smith, C., Vergidis, D., Ellis, P., Macneil, M., and Palmer, M., Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-smallcell lung cancer. J. Clin. Oncol., 23, 6674-6681 (2005). (Pubitemid 46190262)
14. Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., and Zhang, D., Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res., 71, 2466-2475 (2011).
15. Chen, R., Alvero, A. B., Silasi, D. A., and Mor, G., Inflammation, cancer and chemoresistance: taking advantage of the tolllike receptor signaling pathway. Am. J. Reprod. Immunol., 57, 93-107 (2007). (Pubitemid 46099804)
16. Chen, R., Alvero, A. B., Silasi, D. A., Steffensen, K. D., and Mor, G., Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene, 27, 225-233 (2008).
17. Chen, Y. C., Giovannucci, E., Lazarus, R., Kraft, P., Ketkar, S., and Hunter, D. J., Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res., 65, 11771-11778 (2005). (Pubitemid 41821739)
18. Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M. C., Fridman, W. H., Damotte, D., Sautes-Fridman, C., and Cremer, I., Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest., 120, 1285-1297 (2010).
19. Chuang, J. H., Chuang, H. C., Huang, C. C., Wu, C. L., Du, Y. Y., Kung, M. L., Chen, C. H., Chen, S. C., and Tai, M. H., Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. J. Biomed. Sci., 18, 65 (2011).
20. Coley, F. C., A Pseudo-Hypertrophic Family. Br. Med. J., 1, 399-400 (1894).
21. Coussens, L. M. and Werb, Z., Inflammation and cancer. Nature, 420, 860-867 (2002). (Pubitemid 36019639)
22. Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., Weinstein, S., Orel, S. G., Vonderheide, R., Coukos, G., Demichele, A., Araujo, L., Spitz, F. R., Rosen, M., Levine, B. L., June, C., and Zhang, P. J., Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res., 67, 1842-1852 (2007). (Pubitemid 46383411)
23. D'agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., and Garaci, E., Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol., 5, 1205-1212 (2005). (Pubitemid 40725714)
24. D'souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H., and Gillison, M. L., Casecontrol study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med., 356, 1944-1956 (2007). (Pubitemid 46740304)
25. De Cesare, M., Calcaterra, C., Pratesi, G., Gatti, L., Zunino, F., Menard, S., and Balsari, A., Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin. Cancer Res., 14, 5512-5518 (2008).
26. Doan, H. Q., Bowen, K. A., Jackson, L. A., and Evers, B. M., Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res., 29, 2473-2478 (2009).
27. Dorn, A. and Kippenberger, S., Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther., 10, 10-20 (2008). (Pubitemid 351170590)
28. Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A. J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., and Goldmann, T., Human lung cancer cells express functionally active Tolllike receptor 9. Respir. Res., 6, 1 (2005).
29. Dummer, R., Hauschild, A., Becker, J. C., Grob, J. J., Schadendorf, D., Tebbs, V., Skalsky, J., Kaehler, K. C., Moosbauer, S., Clark, R., Meng, T. C., and Urosevic, M., An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res., 14, 856-864 (2008). (Pubitemid 351231170)
30. El-Omar, E. M., Ng, M. T., and Hold, G. L., Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene, 27, 244-252 (2008).
31. Ellerman, J. E., Brown, C. K., De Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., and Lotze, M. T., Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res., 13, 2836-2848 (2007). (Pubitemid 46850704)
32. Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A. J., Subbaramaiah, K., Cooper, H. S., Itzkowitz, S. H., and Abreu, M. T., Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology, 133, 1869-1881 (2007).
33. Garay, R. P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J. F., and Chiavaroli, C., Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol., 563, 1-17 (2007). (Pubitemid 46628799)
34. Geddes, K., Magalhaes, J. G., and Girardin, S. E., Unleashing the therapeutic potential of NOD-like receptors. Nat. Rev. Drug Discov., 8, 465-479 (2009).
35. Gonzalez-Reyes, S., Fernandez, J. M., Gonzalez, L. O., Aguirre, A., Suarez, A., Gonzalez, J. M., Escaff, S., and Vizoso, F. J., Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol. Immunother., 60, 217-226 (2011).
36. Gonzalez-Reyes, S., Marin, L., Gonzalez, L., Gonzalez, L. O., Del Casar, J. M., Lamelas, M. L., Gonzalez-Quintana, J. M., and Vizoso, F. J., Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer, 10, 665 (2010).
37. Goodchild, A., Nopper, N., Craddock, A., Law, T., King, A., Fanning, G., Rivory, L., and Passioura, T., Primary leukocyte screens for innate immune agonists. J. Biomol. Screen., 14, 723-730 (2009).
38. Gorden, K. K., Qiu, X. X., Binsfeld, C. C., Vasilakos, J. P., and Alkan, S. S., Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol., 177, 6584-6587 (2006). (Pubitemid 44715019)
39. Goto, Y., Arigami, T., Kitago, M., Nguyen, S. L., Narita, N., Ferrone, S., Morton, D. L., Irie, R. F., and Hoon, D. S., Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol. Cancer Ther., 7, 3642-3653 (2008).
40. Grimm, M., Kim, M., Rosenwald, A., Heemann, U., Germer, C. T., Waaga-Gasser, A. M., and Gasser, M., Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur. J. Cancer, 46, 2849-2857 (2010).
41. Guo, Z., Chen, L., Zhu, Y., Zhang, Y., He, S., Qin, J., Tang, X., Zhou, J., and Wei, Y., Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and. Oncol. Rep., 27, 396-402 (2012).
42. Hanahan, D. and Weinberg, R. A., The hallmarks of cancer. Cell, 100, 57-70 (2000). (Pubitemid 30046295)
43. Hanten, J. A., Vasilakos, J. P., Riter, C. L., Neys, L., Lipson, K. E., Alkan, S. S., and Birmachu, W., Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol., 9, 39 (2008).
44. Harmey, J. H., Bucana, C. D., Lu, W., Byrne, A. M., Mcdonnell, S., Lynch, C., Bouchier-Hayes, D., and Dong, Z., Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer, 101, 415-422 (2002).
45. Harrison, L. I., Astry, C., Kumar, S., and Yunis, C., Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J. Clin. Pharmacol., 47, 962-969 (2007). (Pubitemid 47094102)
46. Hassan, F., Islam, S., Tumurkhuu, G., Naiki, Y., Koide, N., Mori, I., Yoshida, T., and Yokochi, T., Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer, 6, 281 (2006).
47. He, J. F., Jia, W. H., Fan, Q., Zhou, X. X., Qin, H. D., Shugart, Y. Y., and Zeng, Y. X., Genetic polymorphisms of TLR3 are associated with Nasopharyngeal carcinoma risk in Cantonese population. BMC Cancer, 7, 194 (2007a).
48. He, W., Liu, Q., Wang, L., Chen, W., Li, N., and Cao, X., TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol., 44, 2850-2859 (2007b). (Pubitemid 46412506)
49. Hernandez, Y., Sotolongo, J., Breglio, K., Conduah, D., Chen, A., Xu, R., Hsu, D., Ungaro, R., Hayes, L. A., Pastorini, C., Abreu, M. T., and Fukata, M., The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitisassociated neoplasia. BMC Gastroenterol., 10, 82 (2010).
50. Hold, G. L., Rabkin, C. S., Chow, W. H., Smith, M. G., Gammon, M. D., Risch, H. A., Vaughan, T. L., Mccoll, K. E., Lissowska, J., Zatonski, W., Schoenberg, J. B., Blot, W. J., Mowat, N. A., Fraumeni, J. F., Jr., and El-Omar, E. M., A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology, 132, 905-912 (2007). (Pubitemid 46440859)
51. Hua, D., Liu, M. Y., Cheng, Z. D., Qin, X. J., Zhang, H. M., Chen, Y., Qin, G. J., Liang, G., Li, J. N., Han, X. F., and Liu, D. X., Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol. Immunol., 46, 2876-2884 (2009).
52. Huang, B., Zhao, J., Li, H., He, K. L., Chen, Y., Chen, S. H., Mayer, L., Unkeless, J. C., and Xiong, H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res., 65, 5009-5014 (2005). (Pubitemid 40827306)
53. Huang, B., Zhao, J., Shen, S., Li, H., He, K. L., Shen, G. X., Mayer, L., Unkeless, J., Li, D., Yuan, Y., Zhang, G. M., Xiong, H., and Feng, Z. H., Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res., 67, 4346-4352 (2007). (Pubitemid 46815083)
54. Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., and Xiong, H., TLR signaling by tumor and immune cells: a doubleedged sword. Oncogene, 27, 218-224 (2008).
55. Ilvesaro, J. M., Merrell, M. A., Swain, T. M., Davidson, J., Zayzafoon, M., Harris, K. W., and Selander, K. S., Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-781 (2007). (Pubitemid 46709446)
56. Ioannou, S. and Voulgarelis, M., Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm, 2010 (2010).
57. Ishii, K. J., Kawakami, K., Gursel, I., Conover, J., Joshi, B. H., Klinman, D. M., and Puri, R. K., Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin. Cancer Res., 9, 6516-6522 (2003). (Pubitemid 38031840)
58. Janeway, C. A., Jr. and Medzhitov, R., Innate immune recognition. Annu. Rev. Immunol., 20, 197-216 (2002). (Pubitemid 34293424)
59. Jego, G., Bataille, R., Geffroy-Luseau, A., Descamps, G., and Pellat-Deceunynck, C., Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia, 20, 1130-1137 (2006). (Pubitemid 43797308)
60. Jiang, Q., Wei, H., and Tian, Z., Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer, 8, 12 (2008).
61. Johnson, G. B., Brunn, G. J., Tang, A. H., and Platt, J. L., Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol., 24, 19-24 (2003). (Pubitemid 35462109)
62. Kagan, J. C., Su, T., Horng, T., Chow, A., Akira, S., and Medzhitov, R., TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol., 9, 361-368 (2008). (Pubitemid 351405105)
63. Kanczkowski, W., Tymoszuk, P., Ehrhart-Bornstein, M., Wirth, M. P., Zacharowski, K., and Bornstein, S. R., Abrogation of TLR4 and CD14 expression and signaling in human adrenocortical tumors. J. Clin. Endocrinol. Metab., 95, E421-E429 (2010).
64. Kawai, T. and Akira, S., Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol., 17, 338-344 (2005). (Pubitemid 40848534)
65. Kawai, T. and Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 11, 373-384 (2010).
66. Kelly, M. G., Alvero, A. B., Chen, R., Silasi, D. A., Abrahams, V. M., Chan, S., Visintin, I., Rutherford, T., and Mor, G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res., 66, 3859-3868 (2006).
67. Kikkawa, F., Kawai, M., Oguchi, H., Kojima, M., Ishikawa, H., Iwata, M., Maeda, O., Tomoda, Y., Arii, Y., Kuzuya, K., and Ohta, M., Ishizuka, T., Hattori, S.-E., and Aoki, K., Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur. J. Cancer, 29A, 1542-1546 (1993). (Pubitemid 23251794)
68. Killeen, S. D., Wang, J. H., Andrews, E. J., and Redmond, H. P., Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br. J. Cancer, 100, 1589-1602 (2009).
69. Kim, S., Takahashi, H., Lin, W. W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J. L., and Karin, M., Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457, 102-106 (2009).
70. Kim, W. Y., Lee, J. W., Choi, J. J., Choi, C. H., Kim, T. J., Kim, B. G., Song, S. Y., and Bae, D. S., Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int. J. Gynecol. Cancer, 18, 300-305 (2008). (Pubitemid 351365208)
71. Kochling, J., Prada, J., Bahrami, M., Stripecke, R., Seeger, K., Henze, G., Wittig, B., and Schmidt, M., Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine, 26, 4669-4675 (2008).
72. Krieg, A. M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161-167 (2008).
73. Kundu, S. D., Lee, C., Billips, B. K., Habermacher, G. M., Zhang, Q., Liu, V., Wong, L. Y., Klumpp, D. J., and Thumbikat, P., The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate, 68, 223-229 (2008). (Pubitemid 351186234)
74. Kutikhin, A. G., Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum. Immunol., 72, 1095-1116 (2011).
75. Lee, J. W., Choi, J. J., Seo, E. S., Kim, M. J., Kim, W. Y., Choi, C. H., Kim, T. J., Kim, B. G., Song, S. Y., and Bae, D. S., Increased toll-like receptor 9 expression in cervical neoplasia. Mol. Carcinog., 46, 941-947 (2007).
76. Lee, M. S. and Kim, Y. J., Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem., 76, 447-480 (2007).
77. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., and Hoffmann, J. A., The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 86, 973-983 (1996). (Pubitemid 26336801)
78. Levenga, J., De Vrij, F. M., Oostra, B. A., and Willemsen, R., Potential therapeutic interventions for fragile X syndrome. Trends Mol. Med., 16, 516-527 (2010).
79. Lowe, E. L., Crother, T. R., Rabizadeh, S., Hu, B., Wang, H., Chen, S., Shimada, K., Wong, M. H., Michelsen, K. S., and Arditi, M., Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One, 5, e13027 (2010).
80. Lu, H., Dietsch, G. N., Matthews, M. A., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., Disis, M. L., and Hershberg, R. M., VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin. Cancer Res., 18, 499-509 (2012).
81. Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H., and Karin, M., Inhibition of NF-kappaB in cancer cells converts inflammationinduced tumor growth mediated by TNFalpha to TRAILmediated tumor regression. Cancer Cell, 6, 297-305 (2004). (Pubitemid 39222042)
82. Maehara, Y., Okuyama, T., Kakeji, Y., Baba, H., Furusawa, M., and Sugimachi, K., Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am. J. Surg., 168, 36-40 (1994). (Pubitemid 24331015)
83. Manavalan, B., Basith, S., and Choi, S., Similar structures but different roles - an updated perspective on TLR structures. Front. Physiol., 2, 41 (2011).
84. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F., Cancerrelated inflammation. Nature, 454, 436-444 (2008).
85. Marodi, L., Neonatal innate immunity to infectious agents. Infect. Immun., 74, 1999-2006 (2006).
86. Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., and Mitchell, T. C., The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science, 316, 1628-1632 (2007). (Pubitemid 46982038)
87. Matijevic, T., Marjanovic, M., and Pavelic, J., Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand. J. Immunol., 70, 18-24 (2009).
88. Matzinger, P., Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12, 991-1045 (1994). (Pubitemid 24140436)
89. Matzinger, P., The danger model: a renewed sense of self. Science, 296, 301-305 (2002). (Pubitemid 34303674)
90. Mccall, K. D., Harii, N., Lewis, C. J., Malgor, R., Kim, W. B., Saji, M., Kohn, A. D., Moon, R. T., and Kohn, L. D., High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology, 148, 4226-4237 (2007). (Pubitemid 47295676)
91. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A., Jr., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388, 394-397 (1997). (Pubitemid 27334820)
92. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., and Janeway, C. A., Jr., MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell, 2, 253-258 (1998). (Pubitemid 128373651)
93. Merrell, M. A., Ilvesaro, J. M., Lehtonen, N., Sorsa, T., Gehrs, B., Rosenthal, E., Chen, D., Shackley, B., Harris, K. W., and Selander, K. S., Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res., 4, 437-447 (2006). (Pubitemid 44197039)
94. Miyake, K., Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol., 19, 3-10 (2007). (Pubitemid 46498750)
95. Molteni, M., Marabella, D., Orlandi, C., and Rossetti, C., Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett., 235, 75-83 (2006).
96. Morales, A., Eidinger, D., and Bruce, A. W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116, 180-183 (1976).
97. Murata, M., Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci., 99, 1435-1440 (2008). (Pubitemid 351761735)
98. Ng, L. K., Rich, A. M., Hussaini, H. M., Thomson, W. M., Fisher, A. L., Horne, L. S., and Seymour, G. J., Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma. Br. J. Cancer, 104, 460-463 (2011).
99. Nomi, N., Kodama, S., and Suzuki, M., Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol. Rep., 24, 225-231 (2010).
100. O'neill, L. A., How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol., 18, 3-9 (2006). (Pubitemid 43049641)
101. O'neill, L. A., Fitzgerald, K. A., and Bowie, A. G., The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol., 24, 286-290 (2003).
102. Okamoto, H., Shoin, S., Koshimura, S., and Shimizu, R., Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn. J. Microbiol., 11, 323-326 (1967).
103. Okamoto, M., Oshikawa, T., Tano, T., Ohe, G., Furuichi, S., Nishikawa, H., Ahmed, S. U., Akashi, S., Miyake, K., Takeuchi, O., Akira, S., Moriya, Y., Matsubara, S., Ryoma, Y., Saito, M., and Sato, M., Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J. Natl. Cancer Inst., 95, 316-26 (2003). (Pubitemid 36336482)
104. Pandey, S. and Agrawal, D. K., Immunobiology of Toll-like receptors: emerging trends. Immunol. Cell Biol., 84, 333-341 (2006). (Pubitemid 43882838)
105. Panter, G., Kuznik, A., and Jerala, R., Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther., 11, 133-145 (2009).
106. Picker, L. J. and Butcher, E. C., Physiological and molecular mechanisms of lymphocyte homing. Annu. Rev. Immunol., 10, 561-591 (1992).
107. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y., NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466 (2004). (Pubitemid 39329586)
108. Pimentel-Nunes, P., Afonso, L., Lopes, P., Roncon-Albuquerque, R., Jr., Goncalves, N., Henrique, R., Moreira-Dias, L., Leite-Moreira, A. F., and Dinis-Ribeiro, M. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol. Oncol. Res., 17, 677-683 (2011).
109. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler, B., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 282, 2085-2088 (1998). (Pubitemid 29001265)
110. Qian, Y., Deng, J., Xie, H., Geng, L., Zhou, L., Wang, Y., Yin, S., Feng, X., and Zheng, S. Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J. Cancer Res. Clin. Oncol., 135, 379-386 (2009).
111. Rakoff-Nahoum, S. and Medzhitov, R., Toll-like receptors and cancer. Nat. Rev. Cancer, 9, 57-63 (2009).
112. Rhee, S. H., Im, E., and Pothoulakis, C., Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroen terology, 135, 518-528 (2008).
113. Ronkainen, H., Hirvikoski, P., Kauppila, S., Vuopala, K. S., Paavonen, T. K., Selander, K. S., and Vaarala, M. H., Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J. Exp. Clin. Cancer Res., 30, 84 (2011).
114. Salaun, B., Coste, I., Rissoan, M. C., Lebecque, S. J., and Renno, T., TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol., 176, 4894-4901 (2006).
115. Salaun, B., Zitvogel, L., Asselin-Paturel, C., Morel, Y., Chemin, K., Dubois, C., Massacrier, C., Conforti, R., Chenard, M. P., Sabourin, J. C., Goubar, A., Lebecque, S., Pierres, M., Rimoldi, D., Romero, P., and Andre, F., TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res., 71, 1607-1614 (2011).
116. Sato, M., Harada, K., Yoshida, H., Yura, Y., Azuma, M., Iga, H., Bando, T., Kawamata, H., and Takegawa, Y., Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis, 2, 227-238 (1997). (Pubitemid 127505730)
117. Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H. G., Weller, M., and Pascolo, S., Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol., 36, 2807-2816 (2006). (Pubitemid 44608463)
118. Schmausser, B., Andrulis, M., Endrich, S., Muller-Hermelink, H. K., and Eck, M., Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int. J. Med. Microbiol., 295, 179-185 (2005). (Pubitemid 40776102)
119. Schnare, M., Barton, G. M., Holt, A. C., Takeda, K., Akira, S., and Medzhitov, R., Toll-like receptors control activation of adaptive immune responses. Nat. Immunol., 2, 947-950 (2001). (Pubitemid 32976167)
120. Schon, M. P. and Schon, M., TLR7 and TLR8 as targets in cancer therapy. Oncogene, 27, 190-199 (2008).
121. Sheyhidin, I., Nabi, G., Hasim, A., Zhang, R. P., Ainiwaer, J., Ma, H., and Wang, H., Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J. Gastroenterol., 17, 3745-3751 (2011).
122. Shojaei, H., Oberg, H. H., Juricke, M., Marischen, L., Kunz, M., Mundhenke, C., Gieseler, F., Kabelitz, D., and Wesch, D., Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res., 69, 8710-8717 (2009).
123. Simons, M. P., O'donnell, M. A., and Griffith, T. S., Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol., 26, 341-345 (2008). (Pubitemid 351885380)
124. Song, C., Chen, L. Z., Zhang, R. H., Yu, X. J., and Zeng, Y. X., Functional variant in the 3'-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol. Ther., 5, 1285-1291 (2006). (Pubitemid 44772253)
125. Song, E. J., Kang, M. J., Kim, Y. S., Kim, S. M., Lee, S. E., Kim, C. H., Kim, D. J., and Park, J. H. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int. J. Mol. Med., 28, 115-119 (2011).
126. Spaner, D. E., Shi, Y., White, D., Shaha, S., He, L., Masellis, A., Wong, K., and Gorczynski, R., A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia, 24, 222-226 (2010).
127. Sun, J., Wiklund, F., Zheng, S. L., Chang, B., Balter, K., Li, L., Johansson, J. E., Li, G., Adami, H. O., Liu, W., Tolin, A., Turner, A. R., Meyers, D. A., Isaacs, W. B., Xu, J., and Gronberg, H., Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl. Cancer Inst., 97, 525-532 (2005). (Pubitemid 40590434)
128. Szajnik, M., Szczepanski, M. J., Czystowska, M., Elishaev, E., Mandapathil, M., Nowak-Markwitz, E., Spaczynski, M., and Whiteside, T. L., TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene, 28, 4353-4363 (2009).
129. Szczepanski, M., Stelmachowska, M., Stryczynski, L., Golusinski, W., Samara, H., Mozer-Lisewska, I., and Zeromski, J., Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur. Arch. Otorhinolaryngol., 264, 525-530 (2007). (Pubitemid 46569951)
130. Szczepanski, M. J., Czystowska, M., Szajnik, M., Harasymczuk, M., Boyiadzis, M., Kruk-Zagajewska, A., Szyfter, W., Zeromski, J., and Whiteside, T. L., Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res., 69, 3105-3113 (2009).
131. Takeda, K. and Akira, S., TLR signaling pathways. Semin. Immunol., 16, 3-9 (2004). (Pubitemid 38147427)
132. Takeda, K., Kaisho, T., and Akira, S. Toll-like receptors. Annu. Rev. Immunol., 21, 335-376 (2003). (Pubitemid 37174535)
133. Tang, X. Y., Zhu, Y. Q., Wei, B., and Wang, H., Expression and functional research of TLR4 in human colon carcinoma. Am. J. Med. Sci., 339, 319-326 (2010).
134. Uenishi, Y., Kawabe, K., Nomura, T., Nakai, M., and Sunagawa, M., Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). J. Microbiol. Methods, 77, 139-144 (2009).
135. Vollmer, J. and Krieg, A. M., Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev., 61, 195-204 (2009).
136. Wang, H., Rayburn, E. R., Wang, W., Kandimalla, E. R., Agrawal, S., and Zhang, R., Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol. Cancer Ther., 5, 1585-1592 (2006). (Pubitemid 44070496)
137. Wang, J. H., Manning, B. J., Wu, Q. D., Blankson, S., Bouchier-Hayes, D., and Redmond, H. P., Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J. Immunol., 170, 795-804 (2003). (Pubitemid 36070531)
138. Xu, H., Wu, Q., Dang, S., Jin, M., Xu, J., Cheng, Y., Pan, M., Wu, Y., Zhang, C., and Zhang, Y., Alteration of CXCR7 Expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One, 6, e27399 (2011).
139. Yang, H., Zhou, H., Feng, P., Zhou, X., Wen, H., Xie, X., Shen, H., and Zhu, X., Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J. Exp. Clin. Cancer Res., 29, 92 (2010).
140. Yoneda, K., Sugimoto, K., Shiraki, K., Tanaka, J., Beppu, T., Fuke, H., Yamamoto, N., Masuya, M., Horie, R., Uchida, K., and Takei, Y., Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NFkappaB activation and apoptosis. Int. J. Oncol., 33, 929-936 (2008).
141. Yu, L. and Chen, S., Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother., 57, 1271-1278 (2008).
142. Yu, L., Wang, L., and Chen, S., Exogenous or endogenous Tolllike receptor ligands: which is the MVP in tumorigenesis? Cell. Mol. Life Sci., 69, 935-949 (2012).
143. Zhang, J. J., Wu, H. S., Wang, L., Tian, Y., Zhang, J. H., and Wu, H. L., Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J. Gastroenterol., 16, 2881-2888 (2010).
144. Zhang, Y., Sun, R., Liu, B., Deng, M., Zhang, W., Li, Y., Zhou, G., Xie, P., Li, G., and Hu, J., TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol. Ther., 8, 1826-1830 (2009a).
145. Zhang, Y. B., He, F. L., Fang, M., Hua, T. F., Hu, B. D., Zhang, Z. H., Cao, Q., and Liu, R. Y., Increased expression of Tolllike receptors 4 and 9 in human lung cancer. Mol. Biol. Rep., 36, 1475-1481 (2009b).
146. Zhang, Z. and Schluesener, H. J., Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell. Mol. Life Sci., 63, 2901-2907 (2006). (Pubitemid 46072297)
147. Zheng, S. L., Augustsson-Balter, K., Chang, B., Hedelin, M., Li, L., Adami, H. O., Bensen, J., Li, G., Johnasson, J. E., Turner, A. R., Adams, T. S., Meyers, D. A., Isaacs, W. B., Xu, J., and Gronberg, H., Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res., 64, 2918-2922 (2004). (Pubitemid 38500633)
148. Zhou, M., Mcfarland-Mancini, M. M., Funk, H. M., Husseinzadeh, N., Mounajjed, T., and Drew, A. F., Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol. Immunother., 58, 1375-1385 (2009).
149. Zhou, X. X., Jia, W. H., Shen, G. P., Qin, H. D., Yu, X. J., Chen, L. Z., Feng, Q. S., Shugart, Y. Y., and Zeng, Y. X., Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol. Biomarkers Prev., 15, 862-866 (2006). (Pubitemid 43823509)
150. Zhu, J., Brownlie, R., Liu, Q., Babiuk, L. A., Potter, A., and Mutwiri, G. K., Characterization of bovine Toll-like receptor 8: ligand specificity, signaling essential sites and dimerization. Mol. Immunol., 46, 978-990 (2009).